Pandemic Could Turn Supplement Firms To Drug Production, Helping Fill Public Health Gaps
The Covid-19 pandemic could push food and supplement manufacturers to switch to manufacturing OTC or Rx drugs to help fill public health gaps, says a former deputy director of FDA's Office of Dietary Supplement Programs. Many marketers are well equipped to make OTC drugs, he added in FDLI webinar.
You may also be interested in...
FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.
Purell Battling Class Actions Over Disease Claims While World Scrambles To Increase Hand Sanitizer Supplies
Leading chemical firms, beauty and consumer health companies, even distilleries and medical marijuana cultivators are adapting operations to meet global demand for hand sanitizers amid the COVID-19 pandemic. Meanwhile, plaintiff’s attorneys are busy with multiple class actions against Purell manufacturer GOJO Industries for alleged false advertising following a January warning letter to the firm from the US FDA.
US manufacturers losing ingredient supplies from China may need to qualify more suppliers, potentially requiring tests of all lots, says EAS Consulting. Contract and other manufacturers also should identify alternative sources for materials they receive from China and prepare for shortages from other countries.